Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats - Reportify

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

硕腾(US:ZTS) Businesswire·2025-10-29 20:30

公司产品进展 - Portela成为首个获批用于缓解猫骨关节炎相关疼痛且给药间隔为三个月的单克隆抗体疗法 [1]